Quantum Healthcare reallocates S$3 million placement proceeds to split funding between working capital, MedTech M&A

TriSalus Life Sciences, Inc.
QUANTUM INTERNATIONAL CORP(US)

TriSalus Life Sciences, Inc.

TLSI

0.00

QUANTUM INTERNATIONAL CORP(US)

QUAN

0.00

  • Quantum Healthcare shifted its placement-proceeds plan to split S$ 3 million evenly between working capital and MedTech M&A funding.
  • Revised working-capital allocation raised to S$ 1.5 million to cover overheads such as salaries, rent, administrative costs, professional fees.
  • MedTech acquisition and M&A allocation cut to S$ 1.5 million, with S$ 600,000 advanced to Aios Bio Sciences via a promissory note.
  • Promissory note carries 12% annual interest, repayable on demand, backed by a personal guarantee and a pledge over 10% of Aios Bio Sciences.
  • Funding parked in the promissory note pending M&A execution, as the group does not expect near-term deal completion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum Healthcare Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: C9MK5EGSXHC4MYPI) on June 23, 2026, and is solely responsible for the information contained therein.